Chemotherapy with Cisplatin and 5-fluorouracil Chronomodulated Infusion in Locally Advanced or Metastatic/Recurrent Carcinoma of the Cervix

Miglietta, Loredana; Bruzzone, M; Ghione, G.; Pepe, Alessio; Marenghi, C.; Ragni, Nicola; Boccardo, Francesco

doi:10.1177/030089160208800305

Cited by 7 publications

(2 citation statements)

References 14 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN and RA also possess radiosensitizing activity in vitro . Cisplatin and 5-FU are an effective combination of chemotherapy for cervical cancer and also are radiosensitizers (28)(29)(30) . Therefore, we felt there is a good rationale for combining two effective methods together with radiotherapy in treating locally advanced cervical cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients

Wilailak

Dangprasert

Srisupundit

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

To determine the feasibility and toxicity of a chemoimmunotherapy regimen in combination with radiotherapy in stage IIIB cervical cancer patients, cisplatin 10-20 mg/m2 intravenous (iv) weekly, 5-fluorouracil (5FU) 500 mg/m2 (24-h infusion) weekly, interferon α-2a 3 MU subcutaneously 3 days a week, and 13-cis-retinoic acid 0.5 mg/kg/day orally were given in concurrence with 8-week period of radiotherapy and continued for another 4 weeks after finishing radiotherapy. The dose of cisplatin was escalated from 10 mg/m2 in the first group of three patients (level 1) to 15 mg/m2 in the second group of three patients (level 2) and to 20 mg/m2 in the third group of two patients (level 3) if the former groups could tolerate the drugs well. Patients in levels 1 and 2 had tolerable toxicities. Two patients in level 3 experienced grade 4 leukopenia, so chemoimmunotherapy was discontinued after 2 and 3 cycles orderly. After recovery from toxicities, they continued with radiotherapy. In conclusion, cisplatin 15 mg/m2, 5-FU 500 mg/m2 weekly, interferon α-2a 3 MU subcutaneously 3 days a week, and 13-cis-retinoic acid 0.5 mg/kg/day orally in combination with radiotherapy in stage IIIB cervical cancer patients is tolerable. Leukopenia is the dose-limiting toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients

Wilailak

Dangprasert

Srisupundit

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…IFN and RA also possess radiosensitizing activity in vitro (25–7) . Cisplatin and 5‐FU are an effective combination of chemotherapy for cervical cancer and also are radiosensitizers (28–30) . Therefore, we felt there is a good rationale for combining two effective methods together with radiotherapy in treating locally advanced cervical cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients

Wilailak

Dangprasert

Srisupundit³

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

To determine the feasibility and toxicity of a chemoimmunotherapy regimen in combination with radiotherapy in stage IIIB cervical cancer patients, cisplatin 10-20 mg/m(2) intravenous (iv) weekly, 5-fluorouracil (5FU) 500 mg/m(2) (24-h infusion) weekly, interferon alpha-2a 3 MU subcutaneously 3 days a week, and 13-cis-retinoic acid 0.5 mg/kg/day orally were given in concurrence with 8-week period of radiotherapy and continued for another 4 weeks after finishing radiotherapy. The dose of cisplatin was escalated from 10 mg/m2 in the first group of three patients (level 1) to 15 mg/m(2) in the second group of three patients (level 2) and to 20 mg/m(2) in the third group of two patients (level 3) if the former groups could tolerate the drugs well. Patients in levels 1 and 2 had tolerable toxicities. Two patients in level 3 experienced grade 4 leukopenia, so chemoimmunotherapy was discontinued after 2 and 3 cycles orderly. After recovery from toxicities, they continued with radiotherapy. In conclusion, cisplatin 15 mg/m2, 5-FU 500 mg/m(2) weekly, interferon alpha-2a 3 MU subcutaneously 3 days a week, and 13-cis-retinoic acid 0.5 mg/kg/day orally in combination with radiotherapy in stage IIIB cervical cancer patients is tolerable. Leukopenia is the dose-limiting toxicity.

show abstract

Zervixkarzinom

Schneider¹,

Wendt²,

Meerpohl³

2006

Kompendium Internistische Onkologie

View full text Add to dashboard Cite

Chemotherapy with Cisplatin and 5-fluorouracil Chronomodulated Infusion in Locally Advanced or Metastatic/Recurrent Carcinoma of the Cervix

Cited by 7 publications

References 14 publications

Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients

Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients

Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients

Zervixkarzinom

Contact Info

Product

Resources

About